NeuroMod+: Co-creation for next-generation neuromodulation therapeutics

Award Number
Research Grant
Status / Stage
1 November 2022 -
31 October 2025
Duration (calculated)
02 years 11 months
Funding Amount
Funder/Grant study page
Contracted Centre
Imperial College London
Principal Investigator
Simon Ross Schultz
PI Contact
WHO Catergories
Development of novel therapies
Disease Type
Dementia (Unspecified)

CPEC Review Info
Reference ID757
ResearcherReside Team


Award NumberEP/W035057/1
Status / StageActive
Start Date20221101
End Date20251031
Duration (calculated) 02 years 11 months
Funder/Grant study pageEPSRC
Contracted CentreImperial College London
Funding Amount£1,265,848.00


The Neuromod+ network will represent UK research, industry, clinical and patient communities, working together to address the challenge of minimally invasive treatments for brain disorders. Increasingly, people suffer from debilitating and intractable neurological conditions, including neurodegenerative diseases and mental health disorders. Neurotechnology is playing an increasingly important part in solving these problems, leading to recent bioelectronic treatments for depression and dementia. However, the invasiveness of existing approaches limits their overall impact. Neuromod+ will bring together neurotechnology stakeholders to focus on the co-creation of next generation, minimally invasive brain stimulation technologies. The network will focus on transformative research, new collaborations, and facilitating responsible innovation, partnering with bioethicists and policy makers. As broadening the accessibility of brain modification technology my lead to unintended consequences, considering the ethical and societal implications of these technological development is of the utmost importance, and thus we will build in bioethics research as a core network activity. The activities of NEUROMOD+ will have global impact, consolidating the growing role of UK neurotechnology sector.